NDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
PLENDIL (felodipine) by AstraZeneca is calcium channel antagonists [moa]. First approved in 1991.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PLENDIL (felodipine) is an oral extended-release calcium channel antagonist approved in 1991 for hypertension management. It works by blocking calcium influx into vascular smooth muscle, causing vasodilation and reduced blood pressure. This small-molecule antihypertensive is a foundational therapy in cardiovascular disease prevention.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30), suggesting defensive positioning and potential team rightsizing.
Mechanism of Action
Calcium Channel Antagonists
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Compare the Effects of Lercanidipine Hydrochloride Tablet (Zanidip®) and Felodipine Sustained-Release Tablet for Hypertension
Started Dec 2011
281 enrolled
Hypertension
Evaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal
Started Oct 2008
36 enrolled
Healthy
Use of Ramipril and Felodipine Combination Therapy in Hypertension: An Effectiveness Study With Local Patients in Argentina
Started Jun 2007
271 enrolled
Hypertension
Efficacy and Safety of the Combination of Valsartan Plus Amlodipine in Hypertensive Patients Not Adequately Responding to the Combination Therapy With Ramipril Plus Felodipine
Started Dec 2005
132 enrolled
Hypertension
The Effects on Blood Pressure Control, Pulse Wave Velocity, as Well as Safety and Tolerability of Felodipine Sustained Release in Chinese Patients.
Started Dec 2005
529 enrolled
Hypertension
Worked on PLENDIL at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.